<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Olanzapine - Medications - Offline Clinical Reference</title>
  <link rel="stylesheet" href="../sickbay-shared.css">
</head>
<body>
  <div class="topbar">
    <div class="topbar-inner">
      <span class="pill"><strong>Olanzapine</strong></span>
      <span class="spacer"></span>
      <div class="nav-btns">
        <a class="btn small" href="../../index.html">Home</a>
        <a class="btn small" href="../../index.html#/sickbay-meds">Back to Medications</a>
      </div>
    </div>
  </div>

  <main class="wrap">
    <section class="section">
      <div class="kicker">Neuro / Psych</div>
      <h1>Olanzapine</h1>

      <div class="content">
        <h3>Stocked on board</h3>
        <ul>
          <li>Olanzapine 5mg Tablets</li>
        </ul>

        <div class="rule"></div>

        <h3>Adult dosing</h3>
        <p><strong>Onboard use typically limited to continuation of established therapy or emergency psychiatric stabilization under medical direction</strong></p>
        <ul>
          <li><strong>Acute agitation (IM formulation not stocked onboard; oral dosing for cooperative patient under medical direction)</strong>
            <ul>
              <li>Initial: 5–10 mg PO once (typically 5 mg to start); may repeat after 2 hours if needed and medically directed</li>
            </ul>
          </li>
          <li><strong>Continuation of established schizophrenia/bipolar treatment</strong>
            <ul>
              <li>Follow patient's home regimen (typical maintenance doses range 5–20 mg PO once daily)</li>
              <li>Do not initiate new long-term therapy onboard without specialist consultation</li>
            </ul>
          </li>
          <li><strong>Antiemetic use (off-label; when other agents ineffective and under medical direction)</strong>
            <ul>
              <li>2.5–5 mg PO once or twice daily as needed (lower doses than psychiatric indications)</li>
            </ul>
          </li>
        </ul>

        <div class="rule"></div>

        <h3>Indications</h3>
        <ul>
          <li>Continuation of established treatment for schizophrenia or bipolar disorder (maintenance therapy)</li>
          <li>Acute psychiatric agitation when other measures inadequate and under medical direction/evacuation planning</li>
          <li>Off-label: refractory nausea/vomiting (when conventional antiemetics fail and under medical direction)</li>
        </ul>

        <div class="rule"></div>

        <h3>Contraindications / cautions</h3>
        <ul>
          <li>Hypersensitivity to olanzapine</li>
          <li>Caution in elderly with dementia-related psychosis (increased mortality risk; not approved for this use)</li>
          <li>Diabetes/hyperglycemia risk: olanzapine associated with metabolic effects including new-onset diabetes and diabetic ketoacidosis</li>
          <li>Cardiovascular disease: orthostatic hypotension, QTc prolongation risk</li>
          <li>Hepatic impairment: consider dose reduction and monitor closely</li>
          <li>Sedation/CNS depression: avoid concurrent CNS depressants (alcohol, benzodiazepines) when possible</li>
          <li>Neuroleptic malignant syndrome (NMS) risk: fever, rigidity, altered mental status, autonomic instability (medical emergency)</li>
          <li>Anticholinergic effects: caution in prostatic hypertrophy, narrow-angle glaucoma, constipation/ileus risk</li>
        </ul>

        <div class="rule"></div>

        <h3>Adverse effects</h3>
        <ul>
          <li>Sedation, dizziness, orthostatic hypotension</li>
          <li>Weight gain, increased appetite</li>
          <li>Hyperglycemia, dyslipidemia, metabolic syndrome</li>
          <li>Anticholinergic effects (dry mouth, constipation, urinary retention)</li>
          <li>Extrapyramidal symptoms (less common than older antipsychotics but possible)</li>
          <li>Rare but serious: neuroleptic malignant syndrome, seizures, agranulocytosis</li>
        </ul>

        <div class="rule"></div>

        <h3>Preparation &amp; administration</h3>
        <ul>
          <li>PO tablet; may take with or without food</li>
          <li>If acute psychiatric emergency: ensure safe environment, de-escalation attempts first, and obtain medical direction before administering</li>
          <li>Counsel patient on sedation risk; avoid alcohol and other CNS depressants</li>
          <li>If continuing home therapy: verify dose, confirm patient adherence history, and document clearly</li>
        </ul>

        <div class="rule"></div>

        <h3>Monitoring</h3>
        <ul>
          <li>Mental status and psychiatric symptoms (agitation, psychosis, mood)</li>
          <li>Vital signs: BP (orthostatic changes), HR, temperature (watch for NMS signs)</li>
          <li>Sedation level and fall risk</li>
          <li>Glucose monitoring if diabetic or at risk (olanzapine can worsen glycemic control)</li>
          <li>Extrapyramidal symptoms (tremor, rigidity, akathisia)</li>
          <li>If prolonged use or metabolic risk: weight, lipids, glucose when feasible</li>
        </ul>

        <div class="rule"></div>

        <h3>At-sea considerations</h3>
        <ul>
          <li>Psychiatric emergencies: prioritize safety (patient and crew), de-escalation, and medical consultation/evacuation planning</li>
          <li>For patients on established therapy: ensure adequate supply for voyage duration; confirm adherence and stability before departure</li>
          <li>If administering for acute agitation: document thoroughly (indication, dose, time, response, vital signs, mental status)</li>
          <li>Limited lab/monitoring capability: use with caution in metabolic or cardiovascular risk patients</li>
          <li>Plan for follow-up care at port or evacuation if new psychiatric symptoms or serious adverse effects</li>
        </ul>

        <div class="rule"></div>

        <h3>Online-only references</h3>
        <ul>
          <li>Health Canada product monograph (olanzapine tablets): <a href="https://pdf.hres.ca/dpd_pm/00071247.PDF" target="_blank" rel="noopener">https://pdf.hres.ca/dpd_pm/00071247.PDF</a></li>
          <li>Health Canada product monograph (Zyprexa reference product): <a href="https://pdf.hres.ca/dpd_pm/00061702.PDF" target="_blank" rel="noopener">https://pdf.hres.ca/dpd_pm/00061702.PDF</a></li>
        </ul>
      </div>

      <p class="foot">
        Verify dosing and indications against current clinical guidelines.
      </p>
    </section>
  </main>
</body>
</html>
